Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae and collaborators present data at San Antonio Breast Cancer Symposium demonstrating use of multi-gene panels for reliable risk assessment in hereditary breast/ovarian cancer patients

Invitae and collaborators present data at San Antonio Breast Cancer Symposium demonstrating use of multi-gene panels for reliable risk assessment in hereditary breast/ovarian cancer patients

December 10, 2014

Invitae’s platform demonstrates high concordance with traditional diagnostic tests for BRCA1 and BRCA2 and increased yield of clinical findings in hereditary cancer risk assessment.

SAN ANTONIO – December 10, 2014 – Invitae Corporation, a genetic information company, announced the presentation of two scientific studies at the 37th Annual San Antonio Breast Cancer Symposium: “Clinical Evaluation of Multi-gene Testing for Hereditary Breast and Ovarian Cancer” (Poster P4-12-04) and “Technical Evaluation of Multi-gene Testing for Heredity Breast and Ovarian Cancer” (Poster P4-12-07).  

The ...

Read more


Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider

December 03, 2014

SAN FRANCISCO, December 3, 2014 – Invitae Corporation, a genetic information company, announced that its testing services are eligible for coverage by two additional payors, Blue Shield of California and the Centers for Medicare and Medicaid Services (CMS). 

“Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” said Lisa Alderson, chief commercial officer of Invitae.  “Since launching just over a year ago, we have grown our volume rapidly by offering high ...

Read more


Invitae receives accreditation for its laboratory from the College of American Pathologists

Invitae receives accreditation for its laboratory from the College of American Pathologists

December 02, 2014

SAN FRANCISCO, December 2, 2014 – Invitae Corporation, a genetic information company, announced that it has received accreditation from the College of American Pathologists (CAP). 

The CAP accreditation is awarded to facilities that meet the highest standards of quality in laboratory services. According to the Commission on Laboratory Accreditation, the U.S. government recognizes the CAP Laboratory Accreditation Program, which began in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. 

During the CAP accreditation process ...

Read more


Invitae completes $120 million series F financing

Invitae completes $120 million series F financing

October 13, 2014

SAN FRANCISCO, October 13, 2014 – Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence. 

New investors participating in the round included (in alphabetical order) The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock Springs Capital and Wellington Management Company, LLP, among others ...

Read more


Invitae offers PALB2 testing, providing clinicians with a reliable, fast, affordable option for patients

Invitae offers PALB2 testing, providing clinicians with a reliable, fast, affordable option for patients

August 12, 2014

SAN FRANCISCO - August 12, 2014 - Invitae Corporation, a genetic information company, offers PALB2 testing, providing clinicians with a reliable, fast and affordable option for their cancer patients. Available with a turnaround time of approximately three weeks, the test includes full gene sequencing and deletion/duplication analysis. The test is globally available and is priced at $1,500 in the United States.

A recent multinational study provides compelling evidence that PALB2 is a high-risk breast cancer susceptibility gene (Antoniu et al ...

Read more


Invitae and Nanopharmacia announce partnership to make reliable, fast and affordable hereditary cancer genetic testing broadly available in Mexico

Invitae and Nanopharmacia announce partnership to make reliable, fast and affordable hereditary cancer genetic testing broadly available in Mexico

July 30, 2014

-- Partnership Expands Invitae’s Global Presence into Mexico, Costa Rica, & Panama --

SAN FRANCISCO and MEXICO CITY― July 30, 2014 ― Invitae Corporation, a genetic information company, and Nanopharmacia, the leading oncology molecular test provider in Mexico, today announced an exclusive partnership to make Invitae’s genetic tests for the management of hereditary cancers broadly available throughout Mexico.  In addition, the partnership includes access on a non-exclusive basis in Costa Rica and Panama. 

Nanopharmacia will offer Invitae’s hereditary cancer panels and ...

Read more


Invitae offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast, affordable option for patients

Invitae offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast, affordable option for patients

June 12, 2014

SAN FRANCISCO, June 12, 2014 – Invitae Corporation, a genetic information company, today announced that it now offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast and affordable option for their cancer patients and their families. With results typically available within three weeks, this panel includes an analysis of 17 genes and currently is the most comprehensive panel available. The test is available globally and at a contracted price of $1,500 in the United States. 

The ...

Read more


Invitae announces the availability of its family history tool – A free family history collection app – on Apple’s app store

Invitae announces the availability of its family history tool – A free family history collection app – on Apple’s app store

January 13, 2014

SAN FRANCISCO, January 13, 2014 – Invitae Corporation, a diagnostic genetic information company, today announced that the “Invitae Family History Tool” is now available.  It is a free family history collection app that enables genetic counselors to digitally build, modify, share, and save their patients’ pedigrees.  Available as an iPad and a web app, both versions can be accessed by visiting www.invitae.com/en/family-history/ or by downloading the iPad app directly from Apple’s App Store.

The Invitae Family ...

Read more


Invitae announces Sean George to participate in gene panel during 32nd Annual J.P. Morgan Healthcare Conference

Invitae announces Sean George to participate in gene panel during 32nd Annual J.P. Morgan Healthcare Conference

January 10, 2014

Panel Titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine”

SAN FRANCISCO, January 10, 2014 – Invitae Corporation, a genetic diagnostics company, today announced that Sean George, co-founder of Invitae, is scheduled to speak on a panel titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine” during the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 at 5:00 pm PST in San Francisco ...

Read more

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at ir.invitae.com and follow us on Twitter: @invitae and @invitaeIR